



LAB UPDATE

TRANSITION FROM BNP TO NTpro-BNP

EFFECTIVE DATE: DECEMBER 12, 2019

On December 12, 2019, Mid America Clinical Laboratories will transition testing from BNP to NTpro-BNP at our medium and large hospital laboratories. This transition is part of the migration from chemistry testing on the Abbott Architect to the Ortho Vitros platform.

What is the difference between BNP and NTpro?

While both are used as biomarkers of heart failure, there are some significant differences between the two.

- ENTRESTO – a neprilsyn inhibitory therapy indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.
 - BNP is not a suitable biomarker for patients taking ENTRESTO as the drug interferes with the target molecule and thus measurement.
 - BNP levels would increase during treatment whereas NTpro levels decrease providing a more accurate picture of the patient's status.
- Half-life and Stability
 - BNP has a half life of 20 minutes and a RT stability of 4 hours, which limits the ability to add testing on later as well as determining when the cardiac event started. BNP has a clinical range of 0-5000 pg/mL depending on method.
 - NTpro has a half life of 120 minutes and a stability of 48 hours which makes it very stable, allowing for a better baseline when the patient presents to the ER. NTpro-BNP has a clinical range of 0-35000 pg/mL.
 - This also allows for patients transferring from smaller facilities to be re-baselined at larger facilities without jeopardizing patient care.
- Diagnostic information provided with the NTpro-BNP result is established based on demographic information, providing additional information and guidance to the provider.
 - Normal Ranges
 - 18-74y <125 pg/mL
 - 75y and older <450 pg/mL
 - Interpretation:

The International Collaborative of NT-proBNP Study Data suggests the following Age-Stratified Rule-in-Cut-points to diagnose acute heart failure:

Modality	Age (years)	Optimal Cut Point pg/mL
Diagnosis (rule in HF)	<50	450
	50-75	900
	>75	1800
Exclusion (rule out HF)	N/A	300

Who will be affected?

The following sites will transition to NTpro-BNP, BNP will no longer be orderable for these locations:

St. Vincent Indianapolis	St. Vincent Carmel	St. Vincent Anderson
St. Vincent Kokomo	St. Vincent Heart	

If you have any questions or need more information, please contact:

Terence Cudahy, M.D., Medical Director, Mid America Clinical Laboratories – (317) 803-0253